Friends in India: Please get COVISHIELD or COVAXIN whichever is available to you. Whichever is offered to you. They are both excellent highly effective vaccines.
Ignore the recent drama over the Astra Zeneca press release. Much ado about nothing. @nramind
The initial press release said 79% overall efficacy, with 100% efficacy against hospitalizations and severe disease based on interim analysis.
The primary efficacy analysis shows 76% overall efficacy, with 100% efficacy against hospitalizations and severe disease. @GargiRawat
COVAXIN has reported 81% overall efficacy. @BharatBiotech
There is unnecessary confusion and nitpicking when the message should be one of clarity:
These are amazingly effective vaccines that you should try and get as soon as you can.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Side effects: Milder in my experience than approved lymphoma CAR-Ts. Grade 3 or higher cytokine release syndrome (CRS) in 5% of patients. Grade 3 neurotoxic effects in 3%.
You must concede this is pretty amazing. Epidemiological principles work, even if the pandemic starts in your own backyard with 70,000 cases.
In response to China is not a democracy and so it works argument: No it can be done in a democracy too. S. Korea did it despite starting with 10,000 cases by April 1.
There were countries like Australia and N. Zealand that did it by preventing COVID entry (border control)
But countries like China and S. Korea did the amazing job of containing a highly transmissible respiratory pandemic that already infected thousands within their borders.
For the public to know about Data Safety Monitoring Boards (DSMBs).
Ive been on DSMBs for trials led by colleagues. Those colleagues have been on DSMBs for trials led by me. People in DSMBs don't necessarily have some special superior skills to the study team. And vice versa.
DSMBs in randomized trials get to see data ahead of the study team investigators and decide if any safety concerns and to decide when to stop the trial/release results either because the endpoint was met or there was futility or a safety issue.
The DSMB is independent of the study team and does what is in the best interest of the trial participants and the public.
Their advantage comes from access to data early and without the bias that a study team may have.
Updated progress towards herd immunity in USA:
~30 million have had COVID
~85 million have received at least 1 dose of vaccine
(~70 million are children)
~100 million to go to get 80% of eligible population immune —an overestimate coz it excludes people who had undiagnosed COVID
I'm excluding people who have had COVID by seroprevalence because 1) it's hard to get a good idea of the % for the whole country; 2) the immunity from mild COVID may not be as robust; 3) Im excluding children so it compensates on the other end; 4) meant to be worst case scenario
At the rate we are vaccinating we are within 1-2 months of where we need to be. Which is good news.
I've said for months that we are closer to herd immunity than we think we are. Because of other factors. But that was a soft call. This time with vaccines I'm more confident.